

11-06-00

A/Box/sep

11/03/00

00590609  
01/05/00

00/03/11

# UTILITY PATENT APPLICATION TRANSMITTAL

## (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
DEX-0087

Total Pages in this Submission

**TO THE ASSISTANT COMMISSIONER FOR PATENTS**Box Patent Application  
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING, IMAGING AND  
TREATING CANCER

and invented by:

Recipon et al.

If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_

Enclosed are:

**Application Elements**

1. ☒ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 29 pages and including the following:
  - a. ☒ Descriptive Title of the Invention
  - b. ☒ Cross References to Related Applications (if applicable)
  - c. ☐ Statement Regarding Federally-sponsored Research/Development (if applicable)
  - d. ☐ Reference to Microfiche Appendix (if applicable)
  - e. ☒ Background of the Invention
  - f. ☒ Brief Summary of the Invention
  - g. ☐ Brief Description of the Drawings (if drawings filed)
  - h. ☒ Detailed Description
  - i. ☒ Claim(s) as Classified Below
  - j. ☒ Abstract of the Disclosure

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Small Entity)**

*(Only for new nonprovisional applications under 37 CFR 1.53(b))*

Docket No.  
**DEX-0087**

Total Pages in this Submission

**Application Elements (Continued)**

3. ☐ Drawing(s) *(when necessary as prescribed by 35 USC 113)*  
a. ☐ Formal      b. ☐ Informal      Number of Sheets \_\_\_\_\_
4. ☒ Oath or Declaration  
a. ☐ Newly executed *(original or copy)*      ☒ Unexecuted  
b. ☐ Copy from a prior application (37 CFR 1.63(d)) *(for continuation/divisional application only)*  
c. ☒ With Power of Attorney      ☐ Without Power of Attorney  
d. ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application,  
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference *(usable if Box 4b is checked)*  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6. ☐ Computer Program in Microfiche
7. ☒ Genetic Sequence Submission *(if applicable, all must be included)*  
a. ☒ Paper Copy  
b. ☒ Computer Readable Copy  
c. ☒ Statement Verifying Identical Paper and Computer Readable Copy

**Accompanying Application Parts**

8. ☐ Assignment Papers *(cover sheet & documents)*
9. ☐ 37 CFR 3.73(b) Statement *(when there is an assignee)*
10. ☐ English Translation Document *(if applicable)*
11. ☐ Information Disclosure Statement/PTO-1449      ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Acknowledgment postcard
14. ☒ Certificate of Mailing  
☐ First Class      ☒ Express Mail *(Specify Label No.):* EL156906456US

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Small Entity)**

*(Only for new nonprovisional applications under 37 CFR 1.53(b))*

Docket No.  
**DEX-0087**

Total Pages in this Submission

**Accompanying Application Parts (Continued)**

15. ☐ Certified Copy of Priority Document(s) *(if foreign priority is claimed)*
16. ☐ Small Entity Statement(s) - Specify Number of Statements Submitted: \_\_\_\_\_
17. ☒ Additional Enclosures *(please identify below)*:

Credit Card Payment Form for \$837.00

**Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)**

18. ☐ Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

**Warning**

*An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.*

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Small Entity)**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
**DEX-0087**

Total Pages in this Submission


**Fee Calculation and Transmittal**

**CLAIMS AS FILED**

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	23	- 20 =	3	x \$9.00	\$27.00
Indep. Claims	11	- 3 =	8	x \$40.00	\$320.00
Multiple Dependent Claims (check if applicable) <input checked="" type="checkbox"/>					\$135.00
<b>BASIC FEE</b>					\$355.00
<b>OTHER FEE (specify purpose)</b>					\$0.00
<b>TOTAL FILING FEE</b>					\$837.00

- ☐ A check in the amount of \_\_\_\_\_ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. **12-1086** as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_ as filing fee.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated: November 3, 2000

  
Signature

Kathleen A. Tyrrell  
Reg. No. 38,350  
Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, NJ 08053  
Tel: 856-810-1515  
Fax: 856-810-1454

CC:

DEX-0087

CERTIFICATE OF EXPRESS MAILING


JCS15 U.S. PTO  
09/705500  
11/03/00

"Express Mail" Label No. EL156906456US

Date of Deposit NOVEMBER 3, 2000

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the "BOX SEQUENCE", Assistant Commissioner for Patents, Washington, D.C. 20231.

- 1) Patent Application Transmittal Letter (2 copies);
- 2) Application consisting of 29 pages of Specification, including two (2) pages of Claims, and one (1) page of Abstract;
- 3) Return Post Card;
- 4) Credit Card Payment Form for \$837.00;
- 5) Unexecuted Declaration and Power of Attorney;
- 6) Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§1.821-1.825;
- 7) Sequence listing; and
- 8) Diskette containing computer readable copy of Sequence Listing.

  
KATHLEEN A. TYRELL

**A NOVEL METHOD OF DIAGNOSING,  
MONITORING, STAGING, IMAGING AND TREATING CANCER**

**INTRODUCTION**

This application claims the benefit of provisional U.S.  
5 Application Serial No. 60/163,444, filed November 4, 1999.

**FIELD OF THE INVENTION**

This invention relates, in part, to newly developed  
assays for detecting, diagnosing, monitoring, staging,  
prognosticating, imaging and treating cancers, particularly  
10 lung cancer.

**BACKGROUND OF THE INVENTION**

Lung cancer is the second most prevalent type of cancer  
for both men and women in the United States and is the most  
common cause of cancer death in both sexes. Lung cancer can  
15 result from a primary tumor originating in the lung or a  
secondary tumor which has spread from another organ such as  
the bowel or breast. Primary lung cancer is divided into  
three main types; small cell lung cancer; non-small cell lung  
cancer; and mesothelioma. Small cell lung cancer is also  
20 called "Oat Cell" lung cancer because the cancer cells are a  
distinctive oat shape. There are three types of non-small cell  
lung cancer. These are grouped together because they behave  
in a similar way and respond to treatment differently to small  
cell lung cancer. The three types are squamous cell  
25 carcinoma, adenocarcinoma, and large cell carcinoma. Squamous  
cell cancer is the most common type of lung cancer. It  
develops from the cells that line the airways. Adenocarcinoma  
also develops from the cells that line the airways. However,

adenocarcinoma develops from a particular type of cell that produces mucus (phlegm). Large cell lung cancer has been thus named because the cells look large and rounded when they are viewed under a microscope. Mesothelioma is a rare type of cancer which affects the covering of the lung called the pleura. Mesothelioma is often caused by exposure to asbestos.

Secondary lung cancer is cancer that has started somewhere else in the body (for example, the breast or bowel) and spread to the lungs. Choice of treatment for secondary lung cancer depends on where the cancer started. In other words, cancer that has spread from the breast should respond to breast cancer treatments and cancer that has spread from the bowel should respond to bowel cancer treatments.

The stage of a cancer indicates how far a cancer has spread. Staging is important because treatment is often decided according to the stage of a cancer. The staging is different for non-small cell and for small cell cancers of the lung.

Non-small cell cancer can be divided into four stages. Stage I is very localized cancer with no cancer in the lymph nodes. Stage II cancer has spread to the lymph nodes at the top of the affected lung. Stage III cancer has spread near to where the cancer started. This can be to the chest wall, the covering of the lung (pleura), the middle of the chest (mediastinum) or other lymph nodes. Stage IV cancer has spread to another part of the body.

Since small cell lung cancer can spread quite early in development of the disease, small cell lung cancers are divided into only two groups. These are: limited disease, that is cancer that can only be seen in one lung and in nearby lymph nodes; and extensive disease, that is cancer that has spread outside the lung to the chest or to other parts of the body. Further, even if spreading is not apparent on the scans, it is likely that some cancer cells will have broken away and traveled through the bloodstream or lymph system.

To be safe, it is therefore preferred to treat small cell lung cancers as if they have spread, whether or not secondary cancer is visible. Because surgery is not typically used to treat small cell cancer, except in very early cases, the  
5 staging is not as critical as it is with some other types of cancer. Chemotherapy with or without radiotherapy is often employed. The scans and tests done at first will be used later to see how well a patient is responding to treatment.

Procedures used for detecting, diagnosing, monitoring,  
10 staging, and prognosticating lung cancer are of critical importance to the outcome of the patient. For example, patients diagnosed with early lung cancer generally have a much greater five-year survival rate as compared to the survival rate for patients diagnosed with distant metastasized  
15 lung cancer. New diagnostic methods which are more sensitive and specific for detecting early lung cancer are clearly needed.

Lung cancer patients are closely monitored following initial therapy and during adjuvant therapy to determine  
20 response to therapy and to detect persistent or recurrent disease of metastasis. There is clearly a need for a lung cancer marker which is more sensitive and specific in detecting lung cancer, its recurrence and progression.

Another important step in managing lung cancer is to  
25 determine the stage of the patient's disease. Stage determination has potential prognostic value and provides criteria for designing optimal therapy. Generally, pathological staging of lung cancer is preferable over clinical staging because the former gives a more accurate  
30 prognosis. However, clinical staging would be preferred were it at least as accurate as pathological staging because it does not depend on an invasive procedure to obtain tissue for pathological evaluation. Staging of lung cancer would be improved by detecting new markers in cells, tissues, or bodily  
35 fluids which could differentiate between different stages of



invasion.

U.S. Patent 5,877,290 and U.S. Patent 5,837,498, which are incorporated herein by reference, disclose a human Corpuscles of Stannius, staniocalcin polypeptide and the  
5 nucleic acid sequence encoding this polypeptide. Also disclosed are methods of using this polypeptide for therapeutic purposes such as treatment of electrolyte disorders and disorders due to elevated bone resorption.

It has now been found that this polypeptide and the  
10 nucleic acid encoding this polypeptide, which are referred to herein as Lng108 are diagnostic markers for cancer. Accordingly, in the present invention methods are provided for detecting, diagnosing, monitoring, staging, prognosticating, in vivo imaging and treating cancer via Lng108. Lng108  
15 refers, among other things, to native proteins expressed by the gene comprising the polynucleotide sequence of SEQ ID NO:1 or 2. The deduced amino acid sequence of a polypeptide encoded thereby is depicted in SEQ ID NO:3. By "Lng108" it is also meant herein polynucleotides which, due to degeneracy in  
20 genetic coding, comprise variations in nucleotide sequence as compared to SEQ ID NO: 1 or 2, but which still encode the same protein. In the alternative, what is meant by Lng108 as used herein, means the native mRNA encoded by the gene comprising  
SEQ ID NO:1 or 2 or it can refer to the actual gene comprising  
25 SEQ ID NO:1 or 2, or levels of a polynucleotide which is capable of hybridizing under stringent conditions to the antisense sequence of SEQ ID NO:1 or 2.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in  
30 the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the  
35 disclosed invention will become readily apparent to those

skilled in the art from reading the following description and from reading the other parts of the present disclosure.

#### SUMMARY OF THE INVENTION

Toward these ends, and others, it is an object of the present invention to provide a method for diagnosing the presence cancer by analyzing for changes in levels of Lng108 in cells, tissues or bodily fluids compared with levels of Lng108 in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein a change in levels of Lng108 in the patient versus the normal human control is associated with cancer.

Further provided is a method of diagnosing metastatic cancer in a patient having cancer which is not known to have metastasized by identifying a human patient suspected of having cancer that has metastasized; analyzing a sample of cells, tissues, or bodily fluid from such patient for Lng108; comparing the Lng108 levels in such cells, tissues, or bodily fluid with levels of Lng108 in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in Lng108 levels in the patient versus the normal human control is associated with cancer which has metastasized.

Also provided by the invention is a method of staging cancer in a human with cancer by identifying a human patient having cancer; analyzing a sample of cells, tissues, or bodily fluid from such patient for Lng108; comparing Lng108 levels in such cells, tissues, or bodily fluid with levels of Lng108 in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in Lng108 levels in the patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of Lng108 is associated with a cancer which is regressing or in remission.

Further provided is a method of monitoring cancer in a

human patient for the onset of metastasis. The method comprises identifying a human patient having cancer that is not known to have metastasized; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient  
5 for Lngl08; comparing the Lngl08 levels in such cells, tissue, or bodily fluid with levels of Lngl08 in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in Lngl08 levels in the patient versus the normal human control is associated with a cancer  
10 which has metastasized.

Further provided is a method of monitoring the change in stage of cancer in a human patient by looking at levels of Lngl08 in the human patient. The method comprises identifying a human patient having cancer; periodically analyzing a sample  
15 of cells, tissues, or bodily fluid from such patient for Lngl08; comparing the Lngl08 levels in such cells, tissue, or bodily fluid with levels of Lngl08 in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in Lngl08 levels in the patient  
20 versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of Lngl08 is associated with a cancer which is regressing or in remission.

Further provided are methods of designing new therapeutic  
25 agents targeted to Lngl08 for use in imaging and treating cancer. For example, in one embodiment, therapeutic agents such as antibodies targeted against Lngl08 or fragments of such antibodies can be used to detect or image localization of Lngl08 in a patient for the purpose of detecting or  
30 diagnosing a disease or condition. Such antibodies can be polyclonal, monoclonal, or omniclonal or prepared by molecular biology techniques. The term "antibody", as used herein and throughout the instant specification is also meant to include aptamers and single-stranded oligonucleotides such as those  
35 derived from an *in vitro* evolution protocol referred to as

SELEX and well known to those skilled in the art. Antibodies can be labeled with a variety of detectable labels including, but not limited to, radioisotopes and paramagnetic metals. Therapeutics agents such as small molecules and antibodies  
5 which decrease the concentration and/or activity of Lng108 can also be used in the treatment of diseases characterized by expression of Lng108. Such agents can be readily identified in accordance with the teachings herein.

Other objects, features, advantages and aspects of the  
10 present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various  
15 changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

#### DESCRIPTION OF THE INVENTION

20 The present invention relates to diagnostic assays and methods, both quantitative and qualitative for detecting, diagnosing, monitoring, staging, prognosticating, in vivo imaging and treating cancers by comparing levels of Lng108 with those of Lng108 in a normal human control. Lng108 refers,  
25 among other things, to native proteins expressed by the gene comprising the polynucleotide sequence of SEQ ID NO:1 or 2. The deduced amino acid sequence of a polypeptide encoded thereby is depicted in SEQ ID NO:3. By "Lng108" it is also meant herein polynucleotides which, due to degeneracy in  
30 genetic coding, comprise variations in nucleotide sequence as compared to SEQ ID NO: 1 or 2, but which still encode the same protein. In the alternative, what is meant by Lng108 as used herein, means the native mRNA encoded by the gene comprising SEQ ID NO:1 or 2 or it can refer to the actual gene comprising

SEQ ID NO:1 or 2, or levels of a polynucleotide which is capable of hybridizing under stringent conditions to the antisense sequence of SEQ ID NO:1 or 2. Such levels are preferably measured in at least one of, cells, tissues and/or  
5 bodily fluids, including determination of normal and abnormal levels. Thus, for instance, a diagnostic assay in accordance with the invention for diagnosing over-expression of Lng108 protein compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of  
10 cancers, including lung cancer. Lng108 may be measured alone in the methods of the invention, or, more preferably, in combination with other diagnostic markers for cancer. Thus, it is preferred that the methods of the present invention be employed in combination with measurement of the levels of  
15 other cancer markers as well as Lng108. Other cancer markers, in addition to Lng108, useful in the present invention will depend on the cancer being tested and are known to those of skill in the art.

Detection of Lng108 is particularly useful in lung  
20 cancer. However, this marker is also useful in the diagnosis, prognosis, staging, imaging and treatment of other types of cancer.

#### ***Diagnostic Assays***

The present invention provides methods for diagnosing the  
25 presence of cancer, including lung cancer, by analyzing for changes in levels of Lng108 in cells, tissues or bodily fluids compared with levels of Lng108 in cells, tissues or bodily fluids of preferably the same type from a normal human control, wherein an increase in levels of Lng108 in the  
30 patient versus the normal human control is associated with the presence of cancer.

Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the patient being tested has cancer is one in which cells,  
35 tissues, or bodily fluid levels of a cancer marker, such as

Lng108, are at least two times higher, and most preferable are at least five times higher, than in preferably the same cells, tissues, or bodily fluid of a normal human control.

The present invention also provides a method of  
5 diagnosing metastatic cancer, including metastatic lung cancer, in a patient having a cancer which has not yet metastasized. In the method of the present invention, a human cancer patient suspected of having cancer which may have metastasized (but which was not previously known to have  
10 metastasized) is identified. This is accomplished by a variety of means known to those of skill in the art.

In the present invention, determining the presence of Lng108 in cells, tissues, or bodily fluid, is particularly useful for discriminating between cancers which have not  
15 metastasized and cancers which have metastasized. Existing techniques have difficulty discriminating between a cancer which has metastasized and a cancer which has not metastasized and proper treatment selection is often dependent upon such knowledge.

20 In the present invention, one of the cancer marker levels measured in cells, tissues, or bodily fluid of a human patient is Lng108. Levels in the human patient are compared with levels of Lng108 in preferably the same cells, tissue, or bodily fluid type of a normal human control. That is, if the  
25 cancer marker being observed is Lng108 in serum, this level is preferably compared with the level of Lng108 in serum of a normal human control. An increase in Lng108 in the human patient versus the normal human control is associated with a cancer which has metastasized.

30 Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the cancer in the patient being tested or monitored has metastasized is one in which cells, tissues, or bodily fluid levels of a cancer marker, such as Lng108, are at least two  
35 times higher, and more preferably are at least five times

higher, than in preferably the same cells, tissues, or bodily fluid of a normal human control.

Normal human control as used herein includes a human patient without cancer and/or non cancerous samples from the patient; in the methods for diagnosing or monitoring for metastasis, normal human control may preferably also include samples from a human patient that is determined by reliable methods to have a cancer such as lung cancer which has not metastasized.

#### 10 *Staging*

The invention also provides a method of staging cancers in a human patient. The method comprises identifying a human patient having cancer and analyzing a sample of cells, tissues, or bodily fluid from such patient for Lng108. The measured Lng108 levels are then compared to levels of Lng108 in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in Lng108 levels in the human patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of Lng108 is associated with a cancer which is regressing or in remission.

#### *Monitoring*

Further provided is a method of monitoring cancer in a human patient for the onset of metastasis. The method comprises identifying a human patient having cancer that is not known to have metastasized; periodically analyzing cells, tissues, or bodily fluid from such patient for Lng108; and comparing the Lng108 levels in such cells, tissue, or bodily fluid with levels of Lng108 in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in Lng108 levels in the patient versus the normal human control is associated with a cancer which has metastasized.

Further provided by this invention is a method of monitoring the change in stage of a cancer. The method

comprises identifying a human patient having cancer; periodically analyzing cells, tissues, or bodily fluid from such patient for Lng108; and comparing the Lng108 levels in such cells, tissue, or bodily fluid with levels of Lng108 in  
5 preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in Lng108 levels in the patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease in the levels of Lng108 is associated with a cancer which is  
10 regressing in stage or in remission.

Monitoring such patients for onset of metastasis is periodic and preferably done on a quarterly basis. However, this may be performed more or less frequent depending on the cancer, the particular patient, and the stage of the cancer.

#### 15 ***Prognostic Testing and Clinical Trial Monitoring***

The methods described herein can further be utilized as prognostic assays to identify subjects having or at risk of developing a disease or disorder associated with increased levels of Lng108. The present invention provides a method in  
20 which a test sample is obtained from a human patient and Lng108 is detected. The presence of higher Lng108 levels as compared to normal human controls is diagnostic for the human patient being at risk for developing cancer, particularly lung cancer.

25 The effectiveness of therapeutic agents to decrease expression or activity of Lng108 can also be monitored by analyzing levels of expression of Lng108 in a human patient in clinical trials or in in vitro screening assays such as in human cells. In this way, the gene expression pattern can  
30 serve as a marker, indicative of the physiological response of the human patient, or cells as the case may be, to the agent being tested.

#### ***Detection of genetic lesions or mutations***

The methods of the present invention can also be used to  
35 detect genetic lesions or mutations in Lng108, thereby



determining if a human with the genetic lesion is at risk for cancer or has cancer, particularly lung cancer. Genetic lesions can be detected, for example, by ascertaining the existence of a deletion and/or addition and/or substitution  
5 of one or more nucleotides from Lng108, a chromosomal rearrangement of Lng108, aberrant modification of Lng108 (such as of the methylation pattern of the genomic DNA), the presence of a non-wild type splicing pattern of a mRNA transcript of Lng108, allelic loss of Lng108, and/or  
10 inappropriate post-translational modification of Lng108 protein. Methods to detect such lesions in Lng108 are known to those of skill in the art.

#### **Assay Techniques**

Assay techniques that can be used to determine levels of  
15 gene expression, such as Lng108 of the present invention, in a sample derived from a human are well-known to those of skill in the art. Such assay methods include radioimmunoassays, reverse transcriptase PCR (RT-PCR) assays, immunohistochemistry assays, *in situ* hybridization assays,  
20 competitive-binding assays, Western Blot analyses, ELISA assays and proteomic approaches. Among these, ELISAs are frequently preferred to diagnose a gene's expressed protein in biological fluids.

An ELISA assay initially comprises preparing an antibody,  
25 if not readily available from a commercial source, specific to Lng108, preferably a monoclonal antibody. In addition a reporter antibody generally is prepared which binds specifically to Lng108. The reporter antibody is attached to a detectable reagent such as a radioactive, fluorescent or  
30 enzymatic reagent, for example horseradish peroxidase enzyme or alkaline phosphatase.

To carry out the ELISA, antibody specific to Lng108 is incubated on a solid support, e.g., a polystyrene dish, that binds the antibody. Any free protein binding sites on the  
35 dish are then covered by incubating with a non-specific

protein such as bovine serum albumin. Next, the sample to be analyzed is incubated in the dish, during which time Lng108 binds to the specific antibody attached to the polystyrene dish. Unbound sample is washed out with buffer. A reporter  
5 antibody specifically directed to Lng108 and linked to a detectable reagent such as horseradish peroxidase is placed in the dish resulting in binding of the reporter antibody to any monoclonal antibody bound to Lng108. Unattached reporter antibody is then washed out. Reagents for peroxidase  
10 activity, including a colorimetric substrate are then added to the dish. Immobilized peroxidase, linked to Lng108 antibodies, produces a colored reaction product. The amount of color developed in a given time period is proportional to the amount of Lng108 protein present in the sample.  
15 Quantitative results typically are obtained by reference to a standard curve.

A competition assay can also be employed wherein antibodies specific to Lng108 are attached to a solid support and labeled Lng108 and a sample derived from the patient or  
20 human control are passed over the solid support. The amount of label detected which is attached to the solid support can be correlated to a quantity of Lng108 in the sample.

Using all or a portion of the nucleic acid sequence for Lng108 as a hybridization probe, nucleic acid methods can also  
25 be used to detect Lng108 mRNA as a marker for cancer, including lung cancer. Polymerase chain reaction (PCR) and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASABA), can be used to detect malignant cells for diagnosis and  
30 monitoring of various malignancies. For example, reverse-transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other mRNA species. In RT-PCR, an mRNA species is first reverse transcribed to  
35 complementary DNA (cDNA) with use of the enzyme reverse

transcriptase; the cDNA is then amplified as in a standard PCR reaction. RT-PCR can thus reveal by amplification the presence of a single species of mRNA. Accordingly, if the mRNA is highly specific for the cell that produces it, RT-PCR  
5 can be used to identify the presence of a specific type of cell.

Hybridization to clones or oligonucleotides arrayed on a solid support (i.e., gridding) can be used to both detect the expression of and quantitate the level of expression of  
10 that gene. In this approach, a cDNA encoding the Lngl08 gene is fixed to a substrate. The substrate may be of any suitable type including but not limited to glass, nitrocellulose, nylon or plastic. At least a portion of the DNA encoding the Lngl08 gene is attached to the substrate and then incubated  
15 with the analyte, which may be RNA or a complementary DNA (cDNA) copy of the RNA, isolated from the tissue of interest. Hybridization between the substrate bound DNA and the analyte can be detected and quantitated by several means including but not limited to radioactive labeling or fluorescence labeling  
20 of the analyte or a secondary molecule designed to detect the hybrid. Quantitation of the level of gene expression can be done by comparison of the intensity of the signal from the analyte compared with that determined from known standards. The standards can be obtained by *in vitro* transcription of the  
25 target gene, quantitating the yield, and then using that material to generate a standard curve.

Of the proteomic approaches, 2D electrophoresis is a technique well known to those in the art. Isolation of individual proteins from a sample such as serum is  
30 accomplished using sequential separation of proteins by different characteristics usually on polyacrylamide gels. First, proteins are separated by size using an electric current. The current acts uniformly on all proteins, so smaller proteins move farther on the gel than larger proteins.  
35 The second dimension applies a current perpendicular to the

first and separates proteins not on the basis of size but on the specific electric charge carried by each protein. Since no two proteins with different sequences are identical on the basis of both size and charge, the result of a 2D separation  
5 is a square gel in which each protein occupies a unique spot. Analysis of the spots with chemical or antibody probes, or subsequent protein microsequencing can reveal the relative abundance of a given protein and the identity of the proteins in the sample.

10 The above tests can be carried out on samples derived from a variety cells, bodily fluids and/or tissue extracts (homogenates or solubilized tissue) obtained from the patient including tissue biopsy and autopsy material. Bodily fluids useful in the present invention include blood, urine, saliva,  
15 or any other bodily secretion or derivative thereof. Blood can include whole blood, plasma, serum, or any derivative of blood.

#### *In Vivo Targeting of Lng108/Cancer Therapy*

Identification of Lng108 is also useful in the rational  
20 design of new therapeutics for imaging and treating cancers, and in particular lung cancer. For example, in one embodiment, antibodies which specifically bind to Lng108 can be raised and used *in vivo* in patients suspected of suffering from cancer. Antibodies which specifically bind a Lng108 can  
25 be injected into a patient suspected of having cancer for diagnostic and/or therapeutic purposes. Thus, another aspect of the present invention provides for a method for preventing the onset and treatment of lung cancer in a human patient in need of such treatment by administering to the patient an  
30 effective amount of an antibody. By "effective amount" it is meant the amount or concentration of antibody needed to bind to the target antigens expressed on the tumor to cause tumor shrinkage for surgical removal, or disappearance of the tumor. The binding of the antibody to Lng108 is believed to cause the  
35 death of the cancer cell expressing such Lng108. The

preparation and use of antibodies for *in vivo* diagnosis is well known in the art. For example, antibody-chelators labeled with Indium-111 have been described for use in the radioimmunoscinotographic imaging of carcinoembryonic antigen  
5 expressing tumors (Sumerdon et al. Nucl. Med. Biol. 1990 17:247-254). In particular, these antibody-chelators have been used in detecting tumors in patients suspected of having recurrent colorectal cancer (Griffin et al. J. Clin. Onc. 1991 9:631-640). Antibodies with paramagnetic ions as labels for  
10 use in magnetic resonance imaging have also been described (Lauffer, R.B. Magnetic Resonance in Medicine 1991 22:339-342). Antibodies directed against Lng108 can be used in a similar manner. Labeled antibodies which specifically bind Lng108 can be injected into patients suspected of having  
15 cancer for the purpose of diagnosing or staging of the disease status of the patient. The label used will be selected in accordance with the imaging modality to be used. For example, radioactive labels such as Indium-111, Technetium-99m or Iodine-131 can be used for planar scans or single photon  
20 emission computed tomography (SPECT). Positron emitting labels such as Fluorine-19 can be used in positron emission tomography. Paramagnetic ions such as Gadlinium (III) or Manganese (II) can be used in magnetic resonance imaging (MRI). Localization of the label permits determination of the  
25 spread of the cancer. The amount of label within an organ or tissue also allows determination of the presence or absence of cancer in that organ or tissue.

Antibodies which can be used in *in vivo* methods include polyclonal, monoclonal and omniclonal antibodies and  
30 antibodies prepared via molecular biology techniques. Antibody fragments and aptamers and single-stranded oligonucleotides such as those derived from an *in vitro* evolution protocol referred to as SELEX and well known to those skilled in the art can also be used.

### ***Screening Assays***

The present invention also provides methods for identifying modulators which bind to Lng108 protein or have a modulatory effect on the expression or activity of Lng108 protein. Modulators which decrease the expression or activity of Lng108 protein are believed to be useful in treating cancer, particularly lung cancer. Such screening assays are known to those of skill in the art and include, without limitation, cell-based assays and cell free assays.

Small molecules predicted via computer imaging to specifically bind to regions of Lng108 can also be designed, synthesized and tested for use in the imaging and treatment of cancer. Further, libraries of molecules can be screened for potential anticancer agents by assessing the ability of the molecule to bind to Lng108. Molecules identified in the library as being capable of binding to Lng108 are key candidates for further evaluation for use in the treatment of cancer, particularly lung cancer. In a preferred embodiment, these molecules will downregulate expression and/or activity of Lng108 in cells.

### ***Adoptive Immunotherapy and Vaccines***

Adoptive immunotherapy of cancer refers to a therapeutic approach in which immune cells with an antitumor reactivity are administered to a tumor-bearing host, with the aim that the cells mediate either directly or indirectly, the regression of an established tumor. Transfusion of lymphocytes, particularly T lymphocytes, falls into this category and investigators at the National Cancer Institute (NCI) have used autologous reinfusion of peripheral blood lymphocytes or tumor-infiltrating lymphocytes (TIL), T cell cultures from biopsies of subcutaneous lymph nodes, to treat several human cancers (Rosenberg, S. A., U.S. Patent No. 4,690,914, issued Sep. 1, 1987; Rosenberg, S. A., et al., 1988, N. England J. Med. 319:1676-1680).

The present invention relates to compositions and methods of adoptive immunotherapy for the prevention and/or treatment of primary and metastatic cancer in humans using macrophages sensitized to the antigenic Lng108 molecules, with or without  
5 non-covalent complexes of heat shock protein (hsp). Antigenicity or immunogenicity of Lng108 is readily confirmed by the ability of the Lng108 protein or a fragment thereof to raise antibodies or educate naive effector cells, which in turn lyse target cells expressing the antigen (or epitope).  
10 Cancer cells are, by definition, abnormal and contain proteins which should be recognized by the immune system as foreign since they are not present in normal tissues. However, the immune system often seems to ignore this abnormality and fails to attack tumors. The foreign Lng108 proteins that are  
15 produced by the cancer cells can be used to reveal their presence. The Lng108 is broken into short fragments, called tumor antigens, which are displayed on the surface of the cell. These tumor antigens are held or presented on the cell surface by molecules called MHC, of which there are two types:  
20 class I and II. Tumor antigens in association with MHC class I molecules are recognized by cytotoxic T cells while antigen-MHC class II complexes are recognized by a second subset of T cells called helper cells. These cells secrete cytokines which slow or stop tumor growth and help another type of white  
25 blood cell, B cells, to make antibodies against the tumor cells.

In adoptive immunotherapy, T cells or other antigen presenting cells (APCs) are stimulated outside the body (ex vivo), using the tumor specific Lng108 antigen. The  
30 stimulated cells are then reinfused into the patient where they attack the cancerous cells. Research has shown that using both cytotoxic and helper T cells is far more effective than using either subset alone. Additionally, the Lng108 antigen may be complexed with heat shock proteins to stimulate  
35 the APCs as described in U.S. Patent No. 5,985,270.

The APCs can be selected from among those antigen presenting cells known in the art including, but not limited to, macrophages, dendritic cells, B lymphocytes, and a combination thereof, and are preferably macrophages. In a preferred use, wherein cells are autologous to the individual, autologous immune cells such as lymphocytes, macrophages or other APCs are used to circumvent the issue of whom to select as the donor of the immune cells for adoptive transfer. Another problem circumvented by use of autologous immune cells is graft versus host disease which can be fatal if unsuccessfully treated.

In adoptive immunotherapy with gene therapy, DNA of the Lng108 can be introduced into effector cells similarly as in conventional gene therapy. This can enhance the cytotoxicity of the effector cells to tumor cells as they have been manipulated to produce the antigenic protein resulting in improvement of the adoptive immunotherapy.

Lng108 antigens of this invention are also useful as components of cancer vaccines. The vaccine comprises an immunogenically stimulatory amount of a Lng108 antigen. Immunogenically stimulatory amount refers to that amount of antigen that is able to invoke the desired immune response in the recipient for the amelioration, or treatment of cancer, particularly lung cancer. Effective amounts may be determined empirically by standard procedures well known to those skilled in the art.

The Lng108 antigen may be provided in any one of a number of vaccine formulations which are designed to induce the desired type of immune response, e.g., antibody and/or cell mediated. Such formulations are known in the art and include, but are not limited to, formulations such as those described in U.S. Patent 5,585,103. Vaccine formulations of the present invention used to stimulate immune responses can also include pharmaceutically acceptable adjuvants.



**EXAMPLE**

The present invention is further described by the following example. The example is provided solely to illustrate the invention by reference to specific embodiments.

- 5 This exemplification, while illustrating certain specific aspects of the invention, does not portray the limitations or circumscribe the scope of the disclosed invention.

Experiments described herein were carried out using standard techniques, which are well known and routine to those  
10 of skill in the art, except where otherwise described in detail. Routine molecular biology techniques were carried out as described in standard laboratory manuals, such as Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.  
15 (1989).

**Relative Quantitation of Gene Expression**

Real-Time quantitative PCR with fluorescent Taqman probes is a quantitation detection system utilizing the 5'- 3' nuclease activity of Taq DNA polymerase. The method uses an  
20 internal fluorescent oligonucleotide probe (Taqman) labeled with a 5' reporter dye and a downstream, 3' quencher dye. During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection  
25 System (PE Applied Biosystems, Foster City, CA, USA).

Amplification of an endogenous control was used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH)  
30 or 18S ribosomal RNA (rRNA) was used as this endogenous control. To calculate relative quantitation between all the samples studied, the target RNA levels for one sample were used as the basis for comparative results (calibrator). Quantitation relative to the "calibrator" can be obtained

using the standard curve method or the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).

The tissue distribution, and the level of the target gene for every example in normal and cancer tissue were determined.

5 Total RNA was extracted from normal tissues, cancer tissues, and from cancers and the corresponding matched adjacent tissues. Subsequently, first strand cDNA was prepared with reverse transcriptase and the polymerase chain reaction was done using primers and Taqman probe specific to each target  
10 gene. The results are analyzed using the ABI PRISM 7700 Sequence Detector. The absolute numbers are relative levels of expression of the target gene in a particular tissue compared to the calibrator tissue.

Primers used for expression analysis include:

15 5' TCTAGGTCAGCCCCGAATC 3' (SEQ ID NO:4); and

5' CCTCCAATTCCCCCTTAAACTT 3' (SEQ ID NO:5).

The absolute numbers depicted in Table 1 are relative levels of expression of Lng108 (also referred to as Clone ID 954287; Gene ID 21300) in 12 normal different tissues. All  
20 the values are compared to normal muscle (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

Table 1: Relative Levels of Lng108 Expression in Pooled  
25 Samples

TISSUE	NORMAL
Brain	0.57
Heart	1.63
Kidney	9.55
30 Liver	0.38
Lung	53.46
Mammary Gland	13.00
Muscle	1.00
Prostate	1.69
35 Small Intestine	0.80
Testis	0.56
Thymus	1.06
Uterus	4.88

The relative levels of expression in Table 1 show that Lng108 mRNA is expressed in all 12 tissue types analyzed. The expression level of Lng108 is relatively higher in lung and is lower in brain, liver, small intestine and testis and is medium in kidney, mammary gland and uterus. These results demonstrate that Lng108 mRNA expression is not restricted to lung tissue but is expressed broadly in all tissue types analyzed.

The absolute numbers in Table 1 were obtained analyzing pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 2.

The absolute numbers depicted in Table 2 are relative levels of expression of Lng108 in 48 pairs of matching samples and 2 cancer and 2 normal/normal adjacent tissues of ovary. All the values are compared to normal muscle (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

**Table 2: Relative Levels of Lng108 Expression in Individual Samples**

Sample ID	Cancer Type	Tissue	Cancer	Matching Normal Adjacent
LngAC82	Adenocarcinoma	Lung 1	29.75	28.15
Lng60XL	Adenocarcinoma	Lung 2	28.9	5.3
LngAC66	Adenocarcinoma	Lung 3	5.01	5.50
LngAC69	Adenocarcinoma	Lung 4	58.28	15.19
LngAC88	Adenocarcinoma	Lung 5	90.20	111.0
LngAC13	Adenocarcinoma	Lung 6	18.32	0.00
LngSQ9X	Squamous cell carcinoma	Lung 7	57.88	9.09

	LngQ45	Squamous cell carcinoma	Lung 8	31	76
	LngSQ56	Squamous cell carcinoma	Lung 9	56	65
	LngSQ32	Squamous cell carcinoma	Lung 10	3821.7	218.3
	LngSQ79	Squamous cell carcinoma	Lung 11	574.04	467.88
5	LngC20X	Squamous cell carcinoma	Lung 12	0.7	0.4
	Lng47XQ	Squamous cell carcinoma	Lung 13	204	0.5
	LngSQ44	Squamous cell carcinoma	Lung 14	8.70	61.20
	LngBR94	Squamous cell carcinoma	Lung 15	85.0	0.0
	Lng90X	Squamous cell carcinoma	Lung 16	12.7	7.3
10	LngLC71	Large cell carcinoma	Lung 17	82.14	71.26
	Lng LC109	Large cell carcinoma	Lung 18	94.35	348.50
	Lng75XC	Metastatic from bone cancer	Lung 19	1	3
	LngMT67	Metastatic from renal cell cancer	Lung 20	590.18	20.04
15	LngMT71	Metastatic from melanoma	Lung 21	32.90	18.06
	Bld32XK		Bladder 1	17.5	4.6
	Bld46XK		Bladder 2	3.4	5.8
	ClnAS67		Colon 1	28.4	0.1
	ClnC9XR		Colon 2	29	10
20	ClnTX67		Colon 3	78	2
	End28XA		Endometrium 1	49.2	35.4

	End12XA		Endometrium 2	13	13
	Kid 106XD		Kidney 1	16.6	52.2
5	Kid 107XD		Kidney 2	1992.0	61.0
	Kid 109XD		Kidney 3	641	53
	Liv94XA		Liver 1	30.0	1.6
	Liv15XA		Liver 2	5	3
10	MamA06X		Liver 3	20.9	1.1
	Mam B011X		Mammary gland 1	46.7	0.2
	Mam12X		Mammary gland 2	80	97
	Ovr103X		Ovary 1	44.2	0.9
15	Ovr 10050		Ovary 2	40	
	Ovr1028		Ovary 3	136	
	Ovr18GA		Ovary 4		116
	Ovr206I		Ovary 5		5
20	Pan71XL		Pancreas 1	0.5	0.4
	Pan77X		Pancreas 2	21	7
	Pro20XB		Prostate 1	2.9	15.9
	Pro12B		Prostate 2	11	2
	Pro13XB		Prostate 3	0.6	10
25	SmIH89		Small Intestine 1	28	6
	StoAC44		Stomach 1	8	24
	Tst39X		Testis 1	184.8	1.8
	Utr 135XO		Uterus 1	88.0	138.6
30	Utr 141XO		Uterus 2	110	65
	Utr23XU		Uterus 3	58	41

0= Negative

In the analysis of matching samples, the higher levels of expression were in lung tissue. In addition to the expression in lung, Lng108 was also expressed in all other 14  
5 tissue types tested. These results confirmed that Lng108 is expressed higher in lung but also is expressed in other tissue types analyzed and is consistent with the results obtained with the panel of normal pooled samples (Table 1).

Furthermore, the level of mRNA expression was compared  
10 in cancer samples and the isogenic normal adjacent tissue from the same individual. This comparison provides an indication of specificity for the cancer stage (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 2 shows overexpression of Lng108 in 14 out  
15 of 21 (67%) lung cancer tissues compared with their respective normal adjacent. Overexpression of Lng108 was also found in other cancer samples compared to the normal adjacent tissues (bladder, colon, endometrium, kidney, liver, mammary, ovary, prostate, small intestine, testis and uterus). Overall, these  
20 results show overexpression of Lng108 in 36 out of 48 (75%) cancer tissues tested compared to the normal adjacent.

Thus, the mRNA expression in many different tissue types, plus the observed overexpression in 75% of all the cancer matching samples tested is indicative of Lng108 being a lung  
25 cancer diagnostic marker and a general cancer diagnostic marker.

What is claimed is:

1. A method for diagnosing the presence of cancer in a patient comprising:

(a) determining levels of Lng108 in cells, tissues or  
5 bodily fluids in a patient; and

(b) comparing the determined levels of Lng108 with levels of Lng108 in cells, tissues or bodily fluids from a normal human control, wherein a change in determined levels of Lng108 in said patient versus normal human control is associated with  
10 the presence of cancer.

2. A method of diagnosing metastases of cancer in a patient comprising:

(a) identifying a patient having cancer that is not known to have metastasized;

15 (b) determining Lng108 levels in a sample of cells, tissues, or bodily fluid from said patient; and

(c) comparing the determined Lng108 levels with levels of Lng108 in cells, tissue, or bodily fluid of a normal human control, wherein an increase in determined Lng108 levels in  
20 the patient versus the normal human control is associated with a cancer which has metastasized.

3. A method of staging cancer in a patient having cancer comprising:

(a) identifying a patient having cancer;

25 (b) determining Lng108 levels in a sample of cells, tissue, or bodily fluid from said patient; and

(c) comparing determined Lng108 levels with levels of Lng108 in cells, tissues, or bodily fluid of a normal human control, wherein an increase in determined Lng108 levels in  
30 said patient versus the normal human control is associated with a cancer which is progressing and a decrease in the determined Lng108 levels is associated with a cancer which is regressing or in remission.

4. A method of monitoring cancer in a patient for the  
35 onset of metastasis comprising:

(a) identifying a patient having cancer that is not known to have metastasized;

(b) periodically determining levels of Lng108 in samples of cells, tissues, or bodily fluid from said patient; and

5 (c) comparing the periodically determined Lng108 levels with levels of Lng108 in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically determined Lng108 levels in the patient versus the normal human control is associated with a cancer which has  
10 metastasized.

5. A method of monitoring a change in stage of cancer in a patient comprising:

(a) identifying a patient having cancer;

(b) periodically determining levels of Lng108 in cells,  
15 tissues, or bodily fluid from said patient; and

(c) comparing the periodically determined Lng108 levels with levels of Lng108 in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically determined Lng108 levels in the patient versus  
20 the normal human control is associated with a cancer which is progressing in stage and a decrease is associated with a cancer which is regressing in stage or in remission.

6. A method of identifying potential therapeutic agents for use in imaging and treating cancer comprising screening  
25 molecules for an ability to bind to or decrease expression of Lng108 wherein the ability of a molecule to bind to Lng108 or decrease expression of Lng108 is indicative of the molecule being useful in imaging and treating cancer.

7. A method of imaging cancer in a patient comprising  
30 administering to the patient an antibody which specifically binds to Lng108.

8. The method of claim 7 wherein said antibody is labeled with paramagnetic ions or a radioisotope.

9. A method of treating cancer in a patient comprising  
35 administering to the patient an antibody which specifically



binds to Lng108.

10. The method of claim 9 wherein the antibody is conjugated to a cytotoxic agent.

11. A method of treating cancer in a patient comprising  
5 administering to the patient a molecule which downregulates expression or activity of Lng108.

12. The method of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 wherein the cancer is lung cancer.

13. A method of inducing an immune response against a  
10 target cell expressing Lng108 comprising delivering to a human patient an immunogenically stimulatory amount of a Lng108 protein so that an immune response is mounted against the target cell.

14. A vaccine for treating cancer comprising an  
15 immunogenically stimulating amount of Lng108.

## ABSTRACT

The present invention provides new methods for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating cancer.

10  
20  
30  
40  
50  
60  
70  
80  
90  
100  
110  
120  
130  
140  
150  
160  
170  
180  
190  
200  
210  
220  
230  
240  
250  
260  
270  
280  
290  
300  
310  
320  
330  
340  
350  
360  
370  
380  
390  
400  
410  
420  
430  
440  
450  
460  
470  
480  
490  
500  
510  
520  
530  
540  
550  
560  
570  
580  
590  
600  
610  
620  
630  
640  
650  
660  
670  
680  
690  
700  
710  
720  
730  
740  
750  
760  
770  
780  
790  
800  
810  
820  
830  
840  
850  
860  
870  
880  
890  
900  
910  
920  
930  
940  
950  
960  
970  
980  
990  
1000

Docket No.  
DEX-0087

# Declaration and Power of Attorney For Patent Application

## English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

### A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING, IMAGING AND TREATING CANCER

the specification of which

(check one)

☒ is attached hereto.

☐ was filed on \_\_\_\_\_ as United States Application No. or PCT International Application Number \_\_\_\_\_ and was amended on \_\_\_\_\_

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>

(Filing Date)

(Status)  
(patented, pending, abandoned)

Patent and Trademark Office-U.S. DEPARTMENT OF COMMERCE

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*

Jane Massey Licata, Reg. No. 32,257

Kathleen A. Tyrrell, Reg. No. 38,350

Laura Plunkett, Reg. No. 45,015

of the firm

Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, NJ 08053

Send Correspondence to: Kathleen A. Tyrrell  
Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, NJ 08053

Direct Telephone Calls to: *(name and telephone number)*  
Kathleen A. Tyrrell Tel: 856-810-1515

Full name of sole or first inventor <b>Herve Recipon</b>	
Sole or first inventor's signature	Date
Residence <b>San Francisco, CA</b>	
Citizenship <b>France</b>	
Post Office Address <b>85 Fortuna Avenue</b>	
<b>San Francisco, CA</b>	

Full name of second inventor, if any <b>Roberto A. Macina</b>	
Second inventor's signature	Date
Residence <b>San Jose, CA</b>	
Citizenship <b>Argentina</b>	
Post Office Address <b>4118 Crescendo Avenue</b>	
<b>San Jose, CA</b>	

Full name of third inventor, if any <b>Sei-Yu Chen</b>	
Third inventor's signature	Date
Residence <b>Foster City, CA</b>	
Citizenship <b>Taiwan</b>	
Post Office Address <b>160 Mira Street</b>	
<b>Foster City, CA</b>	

Full name of fourth inventor, if any <b>Yongming Sun</b>	
Fourth inventor's signature	Date
Residence <b>San Jose, CA</b>	
Citizenship <b>China</b>	
Post Office Address <b>869 S. Winchester Blvd., Apt. 260</b>	
<b>San Jose, CA</b>	

Full name of fifth inventor, if any	
Fifth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of sixth inventor, if any	
Sixth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

# SEQUENCE LISTING

<110> Recipon, Herve  
Macina, Roberto A.  
Chen, Sei-Yu  
Sun, Yongming

<120> A Novel Method of Diagnosing, Monitoring, Staging,  
Imaging and Treating Cancer

<130> DEX-0087

<140>

<141>

<150> 60/163,444

<151> 1999-11-04

<160> 5

<170> PatentIn Ver. 2.1

<210> 1

<211> 503

<212> DNA

<213> Homo sapiens

<400> 1

```
ctatatatgt atctacaata catatatcta cacatacaga aagaagcagt tctcacaatg 60
ttgctagttt ttgtcttctc ttccccccac cctactccct ccaattcccc cttaaacttc 120
caaagcttcg tcttgtgttt gctgcagagt gattcggggg ctgacctaga ccagtttgca 180
tgattctctc cttgtgattt gggtgcactt tagacatttt tgtgccatta tatttgcatt 240
atgtatttat aatttaaatg atatttaggt tttggcgtga gtactggaat aaacagtgag 300
catatctggt atatgtcatt atttattggt aaattacatt tttaaagctcc atgtgcata 360
aaaggttatg aaacatatca tggtaatgac agatgcaagt tattttattt gcttattttt 420
ataattaaag atgccatagc ataatatgaa gcctttggtg aattccttct aagataaaaa 480
taataataaa gtgttacgtt tta 503
```

<210> 2

<211> 3762

<212> DNA

<213> Homo sapiens

<400> 2

```
ggtggcagca gcagcatcac acgtaacaac aacaaaaaaa aatcctcacc aaatcctcac 60
ctaagcttcc agtgtatcca gatccacatc ttcactcaag ccaggagagg gaaagaggaa 120
aggggggcag gaaaaaaaaa aaaccaaca acttagcgga aacttctcag agaagtctcc 180
```

aaaaactcagc	agtgtctctg	gtgctgggtg	tcagtgtctc	tgcaacccat	gaggcggagc	240
agaatgactc	tgtgagcccc	aggaatcccc	gagtgggcgc	tcaaaactca	gctgaagtgg	300
ttcgttgtcct	caacagtgct	ctacaggtcg	gctgcggggc	ttttgcatgc	ctggaaaaact	360
ccacctgtga	cacagatggg	atgtatgaca	tctgtaaatc	cttctgtgac	agcgctgtcta	420
aatttgacac	tcaggggaaaa	gcattctgca	aagagagctt	aaaatgcatc	gccaacgggg	480
tcacctccaa	ggctctctcc	gccattcgga	gggtgtccac	tttccaaagg	atgattgtctg	540
agggtcagga	agagtgtctc	agcaagctga	atgtgtgcag	catcgccaag	cggaacctgtg	600
aagccatcac	tgagggtcgt	cagctgccca	atcacttctc	caacagatgc	tataacagac	660
ttgtccgaag	cctgctggaa	tgtgatgaag	acacagtcag	cacaatcaga	gacagcctga	720
tggagaaaa	tgggcctaac	atggccagcc	tcttccacat	ctctgcagaca	gaccactgtg	780
ccccaaacaca	cccaagagct	gacttcaaca	ggagacgcac	caatgagccg	cagaagctga	840
aagtctctct	caggaacctc	cgagggtgag	aggactctcc	ctccccatc	aaacgcacat	900
cccattgagag	tgcataacca	gggagaggtt	attcacacac	tcaccaaatc	agtatcattt	960
ttggggtgtt	gcacaccagg	ttttgagtgt	actgtgcctg	tttgagtttt	tttaaaagt	1020
ttctctattt	ctatccccct	taaagaaaa	tgcatgaaac	taggcttctg	taatacaatat	1080
ccccaacatt	tgcaatggca	gcattccccc	caacaaaaat	catgtgacca	tctgtcctct	1140
cctcagagga	aagtaccctt	ttttaccac	ttcctctgcc	atgttttttc	cctgtctccc	1200
tgagaccacc	ccccaaacaca	aaacattcat	gtaactctcc	agccattgta	atttgaagat	1260
gtggatccct	ttagaacggt	tgccccagta	gagttagctg	ataaggaaac	tttatttaaa	1320
tgcattgtct	aaatgctcat	aaagatgtta	aatggaattc	gtgttatgaa	tctgtgtctgg	1380
ccatggacga	atatgaatgt	cacatttgaa	ttcttgatct	ctaagtagct	agtgtcttat	1440
ggctgtgatc	ctccaatgtc	taattttctt	tcgcacacat	ttaccaaat	gcttgagctc	1500
ggctgtccga	ccagactctg	agcctgcac	ttcttgcatc	taattgaaaa	cgttgatgata	1560
acatctttac	gtactgtaac	tgctcagagc	ttttaaagta	tcttttaaca	ttgtcttaaa	1620
accagagaa	tcaataggtc	aactgtggaa	tataaatagc	tgaaaaacta	tgtactgtac	1680
ataaattcca	gaggactctg	cttaaacaaa	gcagtatata	ataactttat	tcgatataga	1740
tttagttttg	taacttagct	ttatttttct	tttctggga	atggaataac	tatctcactt	1800
ccagatatcc	acataaatgc	tcttctgtgc	cttttttata	actaaggggg	tagaagtagt	1860
tttaattcaa	catcaaaaac	taagatgggc	ctgtatgaga	aggaaaaaac	cacacaggtt	1920
atctgaagga	ccccaggtaa	gatgttaac	tcccagccca	cctcaaccca	gaggctactc	1980
ttgacttaga	ccataactga	aagatctctg	tcacatccaa	ctggaaatcc	caggaaccaa	2040
aaagagcacc	ctatggcctt	ggaccactta	cagtgatgata	aggcctacta	tacatagga	2100
agtggcagtt	ctttactcgt	cccctttcat	cggtgcttgg	tactctggca	aatgatgatg	2160
gggtggggaga	cttttccatt	aatcaatcag	gaatgagtc	atcagccttt	aggtcttttag	2220
tccgggggac	ttgggctgga	gagagtata	ataacccctg	gctgtccagc	cagctggacc	2280
ttctcttaca	ttttcgtctc	gtagcacgct	gcctgccaaa	gtagctcttg	cagctggacc	2340
atctctgtag	gatcgtataa	aaatagaaan	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	2400
nnnnctctgt	gggtgatcat	ttctgccatg	atgttttaca	gatggcgacc	accaagtcac	2460
aacgactaac	ctatctatga	acaacagtag	tttctcaggg	tcactgtcct	tgaacccaac	2520
agtcccttat	gagcgtcact	gcccacacaa	gggtcaatgt	aagagaggaa	gagagggagg	2580
aggggttaga	tcgggagggc	cactccaaac	ctgttaggtt	agaaactatt	gggtgcttag	2640
tctcactagg	ctaaactcaa	gatttgacca	aatcgagtga	tagggatcct	gggtgggagga	2700
gagagggcag	atctccagaa	aaatgaaaag	caatacaact	ttaccataaa	gccttttaaa	2760
ccagtaacgt	gtcgtctcaag	gaccaagagc	aattnnnnnn	nnnnnnnnnn	nnnnnnnnnn	2820
nnnncaacaa	ttgctgcctt	tgctcccaca	cagcctctaa	gcgtgctgac	atcagattgt	2880
taagggcatt	tttataactca	gaactgtccc	atccccaggt	ccccaaactt	atggacactg	2940
ccttagcctc	ttggaaattca	ggtagaccat	attctaagtt	agactcttcc	cctccctccc	3000
acacttccca	ccccaggcca	aggctgactt	ctctgaatca	gaaaagctat	taaagtttgt	3060



```

gtgttgtgtc cattttgcaa acccaactaa gccaggaccc caatgcgaca agtagttcat 3120
gagtatccct agcaaatctt tctctttctt cagtttcagta gatttccttt tttcttntct 3180
ntntnttttt ntnttttttg ctgtgacctc tccaaccgt ggtacccccc cttttctccc 3240
cacgatgata tctatatatg tatctacaat acatatatct acacatacag aaagaagcag 3300
ttctcacaat gttgctagtt ttttgcttct ctttccccc cctactccc tccaattccc 3360
ccttaaaact ccaaagcttc gtcttgtgtt tgctgcagag tgattcgggg gctgacctag 3420
accagtttgc atgattcttc tcttgtgatt tggttgcact tttagacatt ttgtgccatt 3480
atatttgcac tatgtattta taatttaaag gatatttagg tttttggctg agtactggaa 3540
taaacagtga gcatactcgg tatatgtcat tattttattgt taaattacat ttttaagctc 3600
catgtgcata taaagggtat gaaacatatc atggtaataa cagatgcaag ttattttatt 3660
tgcttatttt tataattaaa gatgccatag cataatatga agcctttggg gaattccttc 3720
taagataaaa ataataataa agtgttacgt tttattgggt tc 3762

```

<210> 3

<211> 247

<212> PRT

<213> Homo sapiens

<400> 3

```

Met Leu Gln Asn Ser Ala Val Leu Leu Val Leu Val Ile Ser Ala Ser
  1                      5                      10                      15

```

```

Ala Thr His Glu Ala Glu Gln Asn Asp Ser Val Ser Pro Arg Lys Ser
                20                      25                      30

```

```

Arg Val Ala Ala Gln Asn Ser Ala Glu Val Val Arg Cys Leu Asn Ser
    35                      40                      45

```

```

Ala Leu Gln Val Gly Cys Gly Ala Phe Ala Cys Leu Glu Asn Ser Thr
    50                      55                      60

```

```

Cys Asp Thr Asp Gly Met Tyr Asp Ile Cys Lys Ser Phe Leu Tyr Ser
    65                      70                      75                      80

```

```

Ala Ala Lys Phe Asp Thr Gln Gly Lys Ala Phe Val Lys Glu Ser Leu
                85                      90                      95

```

```

Lys Cys Ile Ala Asn Gly Val Thr Ser Lys Val Phe Leu Ala Ile Arg
    100                      105                      110

```

```

Arg Cys Ser Thr Phe Gln Arg Met Ile Ala Glu Val Gln Glu Glu Cys
    115                      120                      125

```

```

Tyr Ser Lys Leu Asn Val Cys Ser Ile Ala Lys Arg Asn Pro Glu Ala
    130                      135                      140

```

```

Ile Thr Glu Val Val Gln Leu Pro Asn His Phe Ser Asn Arg Tyr Tyr

```

145	150	155	160
Asn Arg Leu Val Arg Ser Leu Leu Glu Cys Asp Glu Asp Thr Val Ser			
165	170	175	
Thr Ile Arg Asp Ser Leu Met Glu Lys Ile Gly Pro Asn Met Ala Ser			
180	185	190	
Leu Phe His Ile Leu Gln Thr Asp His Cys Ala Gln Thr His Pro Arg			
195	200	205	
Ala Asp Phe Asn Arg Arg Arg Thr Asn Glu Pro Gln Lys Leu Lys Val			
210	215	220	
Leu Leu Arg Asn Leu Arg Gly Glu Glu Asp Ser Pro Ser His Ile Lys			
225	230	235	240
Arg Thr Ser His Glu Ser Ala			
245			

<210> 4  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens

<400> 4  
 tctagggtcag cccccgaatc 20

<210> 5  
 <211> 22  
 <212> DNA  
 <213> Homo sapiens

<400> 5  
 cctccaattc ccccttaaac tt 22